Health Care & Life Sciences » Pharmaceuticals | Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
2,151.40
2,362.50
671.10
1,003.90
7,907.50
7,038.80
Depreciation, Depletion & Amortization
1,301.80
1,989.60
2,246.80
2,396.90
2,647.80
2,982.70
Other Funds
-
2,653.00
1,577.30
1,026.40
28.00
1,214.30
Funds from Operations
1,412.00
3,137.90
3,908.90
3,901.60
227.00
2,759.90
Changes in Working Capital
2,158.10
3,555.50
1,967.90
3,332.10
784.80
5,872.70
Net Operating Cash Flow
746.10
6,693.40
5,876.90
569.50
557.70
3,112.70
Capital Expenditures
7,559.50
3,264.80
2,699.40
2,131.10
1,489.10
Purchase/Sale of Investments
2,487.60
769.60
354.50
984.00
11,001.60
Net Investing Cash Flow
5,071.90
6,034.40
2,345.00
3,115.10
9,512.60
Issuance/Reduction of Debt, Net
4,360.00
-
1,700.00
2,400.00
5,700.00
Net Financing Cash Flow
9,154.10
1,662.40
5,194.90
1,147.10
1,947.70
Net Change in Cash
13,479.90
1,003.40
1,663.00
3,692.70
10,902.50
Free Cash Flow
648.70
6,530.20
5,733.90
438.60
833.70
Deferred Taxes & Investment Tax Credit
1,579.90
309.30
490.20
619.60
4,206.80
81.90
Net Assets from Acquisitions
-
2,000.00
-
-
-
Change in Capital Stock
4,794.20
4,315.40
5,317.60
2,520.70
3,724.40

About Cumberland Pharmaceuticals

View Profile
Address
2525 West End Avenue
Nashville Tennessee 37203
United States
Employees -
Website http://www.cumberlandpharma.com
Updated 07/08/2019
Cumberland Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of brands for the hospital acute care, gastroenterology, and oncology. Its product brands include acetadote, caldolor, kristalose, hepatoren, omeclamox, vaprisol, boxaban, vasculan, ethyol, portaban, and totect. The company was founded by A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.